Sector News

Biogen appoints Michel Vounatsos Executive VP, Chief Commercial Officer

March 31, 2016
Life sciences

Biogen today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.

Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of Biogen’s product portfolio and the development of the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team.

“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”

Mr. Vounatsos comes to Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.

“I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world,” said Mr. Vounatsos. “As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”

Source: Biogen

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend